Salute e Benessere
Intravenous Immunoglobulin (IVIG) Market Forecast to Surge During the Forecast Period (2025-2034) with Rising Demand for Autoimmune and Immunodeficiency Treatments | DelveInsight
Discover which therapies are expected to grab the IVIG market share @
The intravenous immunoglobulin market has seen significant growth over the last few years, driven by a combination of factors, including the , the , and . IVIG is used in a variety of indications, from autoimmune diseases like rheumatoid arthritis and lupus to primary and secondary immunodeficiencies. As the global demand for these therapies increases, so does the , with manufacturers needing to ensure that they can meet the growing need for human plasma, a key raw material for IVIG production.
One of the biggest challenges in the IVIG market is the . Plasma collection is a time-intensive process, and the cost of obtaining plasma continues to rise, affecting the . This leads to fluctuating prices for IVIG, making it a significant concern for both healthcare providers and patients. Additionally, the is outpacing the , further exacerbating the supply issue.
On the other hand, , such as the development of more efficient purification techniques, have the potential to improve production yields and reduce costs. The , such as recombinant immunoglobulins and synthetic antibodies, also adds a layer of competition to the traditional IVIG market. However, these alternatives are still in the early stages of adoption, with IVIG maintaining its dominant position due to its proven safety and efficacy profile.
Finally, play a critical role in shaping the IVIG market dynamics. Stringent regulations related to product safety, as well as reimbursement frameworks that vary from region to region, impact market access. into new indications for IVIG, as well as efforts to improve patient outcomes, will be key drivers in shaping the market landscape in the coming years.
Multiple VIG products have been approved in the U.S., each tailored to specific clinical needs. These include .
PRIVIGEN is distinguished as one of the rare IVIG therapies approved in all major markets—the US, EU5, and Japan—demonstrating widespread clinical acceptance and strong regulatory endorsement for the treatment of immune deficiencies and autoimmune diseases.
In recent years, a global shortage of immunoglobulin has become a pressing concern, with Japan notably affected since 2019. The steep increase in demand has necessitated urgent imports. Two major factors driving this demand are the approval of IVIG for halting the progression of chronic inflammatory demyelinating polyneuropathy (CIDP) and the emergence of more concentrated IVIG formulations.
However, scaling up IVIG production and use poses significant challenges. Chief among them is maintaining a consistent plasma donor supply, a task made even harder during the pandemic due to widespread shutdowns of blood collection facilities. Additionally, IVIG must be administered by trained healthcare professionals in clinical settings, which places added strain on both patients and the healthcare infrastructure.
Learn more about the approved IVIG therapies @
Several companies—such as —are actively involved in the development and commercialization of intravenous immunoglobulin therapies, with many already having approved products established in the market.
, developed by , is a low IgA-IgG intravenous immunoglobulin formulation under investigation for treating primary immunodeficiency diseases, especially in patients with IgA hypersensitivity. It is currently undergoing regulatory filing with the FDA and EU for approval in this indication.
The anticipated launch of these emerging therapies are poised to transform the IVIG market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the IVIG market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about IVIG clinical trials, visit @
Intravenous Immunoglobulin (IVIG) is a blood product derived from the pooled plasma of thousands of healthy donors, containing a broad spectrum of immunoglobulin G (IgG) antibodies. It is primarily used to treat patients with immune deficiencies, autoimmune diseases, and certain inflammatory conditions. In individuals with primary immunodeficiency disorders, IVIG helps provide the necessary antibodies their bodies cannot produce, thereby preventing recurrent infections. Additionally, IVIG plays a vital role in immune modulation, dampening harmful autoimmune responses in diseases like Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenic purpura (ITP).
The mechanism of IVIG is complex and multifaceted, involving suppression of pathogenic autoantibodies, modulation of Fc receptors on immune cells, and alteration of cytokine production. Its clinical utility continues to expand, with ongoing research investigating its role in treating conditions like myasthenia gravis, systemic lupus erythematosus, and certain neurological disorders. While generally considered safe, IVIG can cause side effects such as headaches, infusion reactions, and, rarely, thromboembolic events or renal dysfunction, necessitating careful patient selection and monitoring. As a critical therapeutic option in immunology and neurology, IVIG remains a cornerstone for managing diverse immune-mediated disorders.
Primary immunodeficiency diseases had an estimated prevalence of around cases across the EU4 and the UK in 2023. The IVIG market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Discover more about IVIG therapies in development @
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key immune thrombocytopenia companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Guillain-Barre syndrome companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CIDP companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Kawasaki disease companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/intravenous-immunoglobulin-ivig-market-forecast-to-surge-during-the-forecast-period-20252034-with-rising-demand-for-autoimmune-and-immunodeficiency-treatments--delveinsight-302445792.html